Respiratory symptoms associated with the use of azodicarbonamide foaming agent in a plastics injection molding facility.
Respiratory health variables were studied cross-sectionally in 227 employees of a plastics molding facility where numerous complaints had been apparently associated with the use of azodicarbonamide foaming agent in injection molding. Pre- and postshift respiratory status measures and azodicarbonamide concentrations were also obtained for 17 employees. Cross-sectional pulmonary function differences by injection molding status were not observed. Modest decrements in pulmonary function measures were observed between start and end of shift but with no dose-effect relationship. A strong association was observed for injection molding workers for eye/nose/throat irritation, cough, and wheezing. Additionally, wheezing, chest tightness, and symptoms of chronic bronchitis were strongly associated with work in injection molding during periods in which azodicarbonamide was in use. These results suggest respiratory symptom causation by some combination of azodicarbonamide itself, reaction products of azodicarbonamide formed during injection molding, or other unidentified agents uniquely associated with the process of injection molding with azodicarbonamide foaming agent.
D000328:Adult; D001391:Azo Compounds / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D005541:Forced Expiratory Volume; D006801:Humans; D008875:Middle Aged; D009784:Occupational Diseases / Q000139:chemically induced*; D010969:Plastics; D012120:Respiration Disorders / Q000139:chemically induced*; D013997:Time Factors; D014797:Vital Capacity
D001391:Azo Compounds; D010969:Plastics; C004525:azodicarbonamide